We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Has Aytu Bioscience (AYTU) Outpaced Other Medical Stocks This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Aytu Bioscience (AYTU - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Aytu Bioscience is one of 888 individual stocks in the Medical sector. Collectively, these companies sit at #1 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. AYTU is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for AYTU's full-year earnings has moved 90.48% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, AYTU has moved about 62.47% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of -0.44% on a year-to-date basis. This means that Aytu Bioscience is performing better than its sector in terms of year-to-date returns.
Looking more specifically, AYTU belongs to the Medical - Biomedical and Genetics industry, a group that includes 382 individual stocks and currently sits at #25 in the Zacks Industry Rank. On average, stocks in this group have gained 9.40% this year, meaning that AYTU is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track AYTU. The stock will be looking to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Has Aytu Bioscience (AYTU) Outpaced Other Medical Stocks This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Aytu Bioscience (AYTU - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Aytu Bioscience is one of 888 individual stocks in the Medical sector. Collectively, these companies sit at #1 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. AYTU is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for AYTU's full-year earnings has moved 90.48% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, AYTU has moved about 62.47% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of -0.44% on a year-to-date basis. This means that Aytu Bioscience is performing better than its sector in terms of year-to-date returns.
Looking more specifically, AYTU belongs to the Medical - Biomedical and Genetics industry, a group that includes 382 individual stocks and currently sits at #25 in the Zacks Industry Rank. On average, stocks in this group have gained 9.40% this year, meaning that AYTU is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track AYTU. The stock will be looking to continue its solid performance.